专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR20200131862A 종양 특이적 세포 고갈에 대한 항-CD25 审中-公开
公开(公告)号：KR20200131862A
公开(公告)日：2020-11-24
申请号：KR20207029229
申请日：2019-03-13
申请人： TUSK THERAPEUTICS LTD , CANCER RESEARCH TECH LTD
发明人： GOUBIER ANNE , GOYENECHEA CORZO BEATRIZ , SALIMU JOSEPHINE , MOULDER KEVIN , MERCHIERS PASCAL , BROWN MARK , GEOGHEGAN JAMES , PRINZ BIANKA , QUEZADA SERGIO
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00
摘要： 본원의개시내용은인간 CD25에결합하는항체, 특히, CD25의 IL-2로의결합또는 IL-2 신호전달을차단하지않는, 항CD25-a-646 항체에서발견되는항체서열을제공한다. 청구된항체는 CD25 상에에피토프: PHATFKAMA YKEGTM (42-56)에결합한다. 상기서열을포함하는, 항체및 이의항원-결합부분은약제학적조성물및 치료방법, 특히암을치료하기위한방법에사용될수 있다.

2. 发明公开

KR20200144109A BCL6 저해제 审中-公开
公开(公告)号：KR20200144109A
公开(公告)日：2020-12-28
申请号：KR20207032149
申请日：2019-04-12
申请人： CANCER RESEARCH TECH LTD , THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL
发明人： BELLENIE BENJAMIN RICHARD , CHEUNG KWAI MING JACK , DAVIS OWEN ALEXANDER , HOELDER SWEN , HUCKVALE ROSEMARY , COLLIE GAVIN , MENICONI MIRCO , BRENNAN ALFIE , LLOYD MATTHEW GARTH
IPC分类号： C07D498/04 , A61K31/5383 , A61K31/542 , A61K31/553 , A61K31/554 , A61P35/00 , C07D471/04 , C07D498/08 , C07D498/14 , C07D498/20 , C07D513/04
摘要： 본발명은 BCL6(B-세포림프종 6) 활성의저해제로서기능하는하기화학식 I의화합물(식중 X1, X2, R1, R2, R30, R31 및고리 A는각각본 명세서에정의된바와같음)에관한것이다. 본발명은또한이러한화합물의제조방법, 이들을포함하는약제학적조성물, 및 BCL6 활성이연관된증식성장애, 예컨대, 암, 뿐만아니라다른질병또는질환의치료에서의이들의용도에관한것이다. [화학식 I] JPEGpct00220.jpg5555

3. 发明公开

KR20200131286A 종양 특이적 세포 고갈에 대한 항-CD25 审中-公开
公开(公告)号：KR20200131286A
公开(公告)日：2020-11-23
申请号：KR20207029205
申请日：2019-03-13
申请人： TUSK THERAPEUTICS LTD , CANCER RESEARCH TECH LTD
发明人： GOUBIER ANNE , GOYENECHEA CORZO BEATRIZ , SALIMU JOSEPHINE , MOULDER KEVIN , MERCHIERS PASCAL , BROWN MARK , GEOGHEGAN JAMES , PRINZ BIANKA , QUEZADA SERGIO
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00
摘要： 본원의개시내용은인간 CD25에결합하는항체, 특히, CD25의 IL-2로의결합또는 IL-2 신호전달을차단하지않는, 항-CD25-a-674 항체에서발견되는항체서열을제공한다. 청구된항체는 CD25 상에에피토프: QCVQGYRA 및 RWTQPQLICTG에결합한다. 상기서열을포함하는, 항체및 이의항원-결합부분은약제학적조성물및 치료방법, 특히암을치료하기위한방법에사용될수 있다.

4. 发明公开

KR20200131861A 종양 특이적 세포 고갈에 대한 항-CD25 审中-公开
公开(公告)号：KR20200131861A
公开(公告)日：2020-11-24
申请号：KR20207029221
申请日：2019-03-13
申请人： TUSK THERAPEUTICS LTD , CANCER RESEARCH TECH LTD
发明人： GOUBIER ANNE , GOYENECHEA CORZO BEATRIZ , SALIMU JOSEPHINE , MOULDER KEVIN , MERCHIERS PASCAL , BROWN MARK , GEOGHEGAN JAMES , PRINZ BIANKA , QUEZADA SERGIO
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00
摘要： 본원의개시내용은인간 CD25에결합하는항체, 특히, CD25의 IL-2로의결합또는 IL-2 신호전달을차단하지않는, 항CD25-a-686 항체에서발견되는항체서열을제공한다. 청구된항체는 CD25 상에에피토프: NSSHSSWDNQCQCTS (70 내지 84)에결합한다. 상기서열을포함하는, 항체및 이의항원-결합부분은약제학적조성물및 치료방법, 특히암을치료하기위한방법에사용될수 있다.

5. 发明专利

ZA202003845B FUSION PROTEINS 未知
公开(公告)号：ZA202003845B
公开(公告)日：2022-12-21
申请号：ZA202003845
申请日：2020-06-24
申请人： CANCER RESEARCH TECH LTD
发明人： FRANCIS JAY MUSSAI , CARMELA DE SANTO , STEVEN LEE
摘要： Provided are fusion target-binding proteins comprising a target binding moiety, an intracellular signalling region and a domain that promotes synthesis of arginine or an arginine precursor. The domain may be an enzyme domain such as an argininosuccinate synthase (ASS-1) enzyme domain, or an ornithine transcarbamylase (OTC) enzyme domain. Also provided are cells comprising such a fusion target-binding protein (for example cells that express the fusion target-binding protein), and nucleic acids encoding such fusion target-binding proteins. The invention also provides fusion target-binding proteins comprising a target binding moiety, an intracellular signalling region and a domain that promotes synthesis of tryptophan or a tryptophan precursor. Pharmaceutical compositions, medical uses, and methods of treatment, all using the fusion target-binding proteins, cells, or nucleic acids are disclosed. The proteins, cells, nucleic acids and pharmaceutical compositions may be used in the prevention and/or treatment of cancer, such as neuroblastoma or acute myeloid leukaemia.

6. 发明专利

BR112016011078B1 DERIVADOS DE 1-(5-TERC-BUTIL-2-ARIL-PIRAZOL-3-IL)-3-[2-FLÚOR-4-[(3- OXO-4H-PIRIDO[2,3-B]PIRAZIN-8-IL)ÓXI]FENIL]UREIA, SEUS USOS, SUA COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA PREPARAR A MESMA E MÉTODO IN VITRO PARA INIBIR A FUNÇÃO RAF EM UMA CÉLULA 未知
公开(公告)号：BR112016011078B1
公开(公告)日：2022-12-06
申请号：BR112016011078
申请日：2014-11-25
申请人： CANCER RESEARCH TECH LTD , INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL THE
发明人： CAROLINE JOY SPRINGER , RICHARD MARAIS , ROMINA GIROTTI , DAN NICULESCU-DUVAZ , ION NICULESCU-DUVAZ , ALFONSO ZAMBON
IPC分类号： C07D471/04 , A61K31/4985 , A61P35/00
摘要： DERIVADOS DE 1-(5-TERC-BUTIL-2-ARIL- PIRAZOL-3-IL)-3-[2-FLÚOR-4-[(3-OXO-4H-PIRIDO[2,3-B] PIRAZIN-8- IL)ÓXI]FENIL]UREIA, SEUS USOS, SUA COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA PREPARAR A MESMA E MÉTODO IN VITRO PARA INIBIR A FUNÇÃO RAF EM UMA CÉLULA. A presente invenção refere-se geralmente ao campo dos compostos terapêuticos. Mais especificamente, a presente invenção refere-se a certos compostos de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-flúor-4-[(3-oxo-4H-pirido[2,3-b]pirazin-8-il)óxi]fenil]ureia (referidos no presente documento como "compostos TBAP") que, nomeadamente, inibem RAF (por exemplo, BRAF, CRAF; etc.) A presente invenção também refere-se a composições farmacêuticas compreendendo esses compostos, e ao uso desses compostos e composições, tanto in vitro como in vivo, para inibir RAF (por exemplo, BRAF, CRAF, etc.); e para o tratamento de distúrbios, incluindo: distúrbios proliferativos; câncer (incluindo, por exemplo, melanoma maligno, carcinoma colorretal, adenocarcinoma do pâncreas); inflamação; distúrbios imunológicos; infecções virais; doenças fibrôticas; distúrbios associados com uma forma mutada de RAF (por exemplo, BRAF, CRAF, etc.); distúrbios melhorados pela inibição de RAF (por exemplo, BRAF, CRAF, etc); distúrbios melhorados pela inibição de BRAF mutante; distúrbios melhorados pela inibição de BRAF e CRAF; distúrbios associados a mutações de RAS e/ou ativação da via de MAPK; distúrbios melhorados pela inibição de SRC, p38, FGFRA, VEGFR-2 (KDR), e/ou LCK; etc.

7. 发明专利

AU2021255917A1 Modulation of T cell cytotoxicity and related therapy 未知
公开(公告)号：AU2021255917A1
公开(公告)日：2022-11-17
申请号：AU2021255917
申请日：2021-04-16
申请人： CANCER RESEARCH TECH LTD
发明人： QUEZADA SERGIO , PEGGS KARL , SWANTON CHARLES , GHORANI EHSAN , READING JAMES , GALVEZ-CANCINO FELIPE , KARAGIANNI DESPOINA
IPC分类号： A61K35/17 , A61P35/00
摘要： The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder, wherein the engineered T cell has modulated expression of one or more genes selected from

8. 发明专利

IL289793B Heterocyclic compounds as ret kinase inhibitors 未知
公开(公告)号：IL289793B
公开(公告)日：2022-11-01
申请号：IL28979322
申请日：2022-01-12
申请人： CANCER RESEARCH TECH LTD
IPC分类号： A61P35/00
摘要： The present invention relates to compounds of Formula Ig that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity:The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

9. 发明专利

RS63609B1 HETEROCIKLIČNA JEDINJENJA KAO INHIBITORI RET KINAZE 未知
公开(公告)号：RS63609B1
公开(公告)日：2022-10-31
申请号：RSP20220803
申请日：2017-04-18
申请人： CANCER RESEARCH TECH LTD
发明人： JORDAN ALLAN , NEWTON REBECCA , WASZKOWYCZ BOHDAN , SUTTON JONATHAN MARK , HYND GEORGE , PAOLETTA SILVIA , FORDYCE EUAN ALEXANDER FRASER
IPC分类号： A61K31/519 , A61K31/437 , A61K31/53 , A61P35/00 , C07D471/04 , C07D487/04 , C07D519/00

10. 发明专利

LT3442535T HETEROCIKLINIAI JUNGINIAI KAIP RET KINAZĖS INHIBITORIAI 未知
公开(公告)号：LT3442535T
公开(公告)日：2022-10-25
申请号：LT17051077
申请日：2017-04-18
申请人： CANCER RESEARCH TECH LTD
发明人： JORDAN ALLAN , NEWTON REBECCA , WASZKOWYCZ BOHDAN , SUTTON JONATHAN , HYND GEORGE , PAOLETTA SILVIA , FORDYCE EUAN ALEXANDER FRASER
IPC分类号： A61K31/519 , A61K31/437 , A61K31/53 , A61P35/00 , C07D471/04 , C07D487/04 , C07D519/00

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式